Viemed Healthcare, Inc. a home medical equipment supplier and the nation’s largest independent provider of ventilation that provides post-acute respiratory care services, announced today that the Company’s Chief Medical Officer, Dr. William Frazier, ABIM Board Certified in Internal, Pulmonary, Critical Care, and Sleep Disorders Medicine and leader of two peer reviewed clinical studies concerning the benefits of ...

Viemed Healthcare, Inc. (the " Company " or " Viemed ") (NASDAQ: VMD and TSX: VMD.TO), a home medical equipment supplier and the nation's largest independent provider of ventilation that provides post-acute respiratory care services, announced today that the Company's Chief Medical Officer, Dr. William Frazier, ABIM Board Certified in Internal, Pulmonary, Critical Care, and Sleep Disorders Medicine and leader of two peer reviewed clinical studies (the "recent studies") concerning the benefits of Non-Invasive Ventilation at Home (NIVH) therapy in COPD-CRF patients, will be sharing his professional insights and perspective during a free public Webinar on December 9 at 12:00 p.m. EST.


EVENT: Learn how non-invasive ventilation at home treatment has proven to reduce healthcare utilization for COPD-CRF patients.
WHAT: Complimentary Webinar with Viemed Chief Medical Officer, Dr. William Frazier, including live Q&A session immediately following study presentation.
WHEN: Thursday, December 9, 2021, 12:00 p.m.-1:00 p.m. EST
WHERE: Virtual - Via Zoom

Research conducted in relation to the recent studies provides clear clinical evidence that patients with COPD-CRF who received NIVH had statistically significant and clinically meaningful reductions in hospitalizations and emergency department visits compared with patients not treated with NIVH. Furthermore, the data from such studies suggest that earlier NIVH treatment following a Chronic Respiratory Failure (CRF) diagnosis is associated with a considerable reduction in all-cause mortality.

As Viemed's Chief Medical Officer, Dr. Frazier has been on the vanguard of this therapy in the U.S., where currently only 5 percent of COPD eligible patients are utilizing NIVH, as compared to Europe and other parts of the world where it is more widely adopted. The recent studies and related Webinar are a timely educational resource following last month's National COPD Awareness Month , sponsored by The National Heart, Lung, and Blood Institute, which cites COPD as a significant cause of disability and the nation's fourth leading cause of death.

"We believe these studies are groundbreaking U.S.-based medical evidence that set a gold standard, confirming that COPD-CRF patients who utilize NIVH therapy will live longer, go to the hospital less, and require fewer emergency room visits, providing a real quality of life improvement," remarked Dr. Frazier. "We believe that we also have proven definitively that early NIVH intervention results in better outcomes; ideally within the first 60 days," he further added.

The recent studies are available in the following respective journals: " Noninvasive Ventilation at Home Reduces Mortality in COPD with CRF," The American Journal of Managed Care , September 15, 2021 ( ) and "Non-invasive Ventilation at Home Improves Survival and Decreases Healthcare Utilization in Medicare Beneficiaries with COPD-CRF," Respiratory Medicine , December 29, 2020 ( ).


Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed's service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Visit our website at .

For further information, please contact:

Glen Akselrod
Bristol Capital

Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.

Maura Nelson, Director Brand Marketing
VieMed Healthcare
866-852-8343, x1175

Forward-Looking Statements

Certain statements contained in this press release (and oral statements regarding the subject matter of this press release, including those made on the Webinar announced herein) may constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "potential", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", or "projects", or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results "will", "should", "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties, and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the Company operates; the impact of the COVID-19 pandemic and the actions taken by governmental authorities, individuals and companies in response to the pandemic on our business, financial condition and results of operations, including on the Company's patient base, revenues, employees, and equipment and supplies; significant capital requirements and operating risks that the Company may be subject to; the ability of the Company to implement business strategies and pursue business opportunities; volatility in the market price of the Company's common shares; the Company's novel business model; the risk that the clinical application of treatments that demonstrate positive results in a study may not be positively replicated or that such test results may not be predictive of actual treatment results or may not result in the adoption of such treatments by providers; the state of the capital markets; the availability of funds and resources to pursue operations; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers and the recall of certain Royal Philips BiPAP and CPAP devices and ventilators that we distribute and sell; granting of permits and licenses in a highly regulated business; competition; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company's status as an emerging growth company; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, such as the COVID-19 pandemic, and claims resulting from such events or concerns; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the "SEC") available on the SEC's website at, including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

IDBS Polar Insight Brings Advanced Data Analytics and Visualization to BioPharma Lifecycle Management

IDBS, a Danaher (NYSE:DHR) operating company, announced Polar Insight, bringing new advanced data analytics and visualization tools to the Polar BioPharma Lifecycle Management (BPLM) platform.

Extracting valuable insights from process and quality data across the biopharmaceutical lifecycle is a time consuming and error prone process, requiring laborious manual work and multiple steps.

Keep reading... Show less

Medtronic receives Health Canada licence for GI Genius intelligent endoscopy module with artificial intelligence system for colonoscopy

Transformative AI System Enhances Colorectal Cancer Detection Capabilities

 Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) — the global leader in medical technology — announced it has received a Health Canada licence for the GI Genius™ intelligent endoscopy module. GI Genius is a computer-aided detection (CADe) system that uses artificial intelligence (AI) to highlight regions of the colon suspected to have visual characteristics consistent with different types of mucosal abnormalities.

Keep reading... Show less
Beyond Medical Technologies Ramps Up COVID Mask Manufacturing in Response to New South Africa COVID Variant

Beyond Medical Technologies Ramps Up COVID Mask Manufacturing in Response to New South Africa COVID Variant

Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) ("Beyond Medical" or the "Company") is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. ("Micron Technologies").

Keep reading... Show less
Leveljump Q3 Earnings and Results; Record Quarterly Revenues

Leveljump Q3 Earnings and Results; Record Quarterly Revenues

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce today it has reported financial results for the third fiscal quarter ended September 30th, 2021. All amounts are expressed in Canadian dollars.

Financial and Operational Highlights

Keep reading... Show less

Thermo Fisher Scientific Confirms Detection of SARS-CoV-2 in Samples Containing the Omicron Variant with its TaqPath COVID-19 Tests

- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit *, and TaqPath COVID-19 CE-IVD RT-PCR Kit *, which test for the presence of SARS-CoV-2, are not impacted by the emerging B.1.1.529, or Omicron variant, enabling accurate test results.

The Omicron variant, which was designated a " variant of concern " by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone. The WHO has reported that preliminary evidence suggests an increased risk of transmission compared to other variants of concern. This designation and information are leading to renewed travel restrictions and research to examine the variant's impact on efficacy of existing vaccines and tests. The WHO and European Centers for Disease Control have both reported that using S-gene target failure (SGTF) of the PCR assays as a proxy for the variant helped to identify Omicron. Cases of the variant were first identified in South Africa and have now been reported in at least a dozen countries around the world.

Keep reading... Show less
UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical

UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that, subject to regulatory approval, it has agreed to acquire an outstanding 14.6% minority equity interest in Real Time Medical Inc. ("RTM"), a private Ontario company, in exchange for 2,494,576 units (a "Unit") of Leveljump. Each Unit will be issued at a price of $0.66 per Unit with each Unit being comprised of three (3) Leveljump common shares at a deemed price of $0.22 per share and one (1) share purchase warrant of Leveljump, each warrant entitling the holder to acquire one additional common share of Leveljump at a price of $0.35 per common share on or before December 31, 2023.

The equity interest in RTM was acquired through a mini-tender offer to the shareholders of RTM dated November 1, 2021 whereby JUMP offered to acquire up to 19.9% of RTM in exchange for the Units. The holders of the RTM shares who have tendered are all accredited investors.

Keep reading... Show less

Top News

Related News